Opus Genetics Announces Five Gene Therapy Programs in Press Release

What Happened
On June 16, 2026, Opus Genetics, Inc. (a Delaware corporation) announced via press release — furnished to the SEC under Item 7.01 (Regulation FD Disclosure) — that it is highlighting five gene therapy programs targeting significant unmet needs in patients with inherited retinal diseases. The press release was furnished as Exhibit 99.1 to the company’s Form 8-K filing.

Key Details

• Date filed: June 16, 2026 (Form 8-K reporting Regulation FD disclosure).
• Announcement: Press release titled “Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases.”
• Filing exhibits: Press release provided as Exhibit 99.1; cover page interactive XBRL file included as Exhibit 104.1.
• No financial results, management changes, or transaction disclosures were included in this filing.

Why It Matters
This filing is a public disclosure of Opus Genetics’ clinical and product-development focus—specifically five gene therapy programs for inherited retinal diseases—which can affect investor awareness of the company’s pipeline progress. Because the item is a Regulation FD disclosure, the information was broadly communicated to ensure fair public access. The 8-K does not contain earnings, guidance, or material contracts, so investors should look for future filings or releases for clinical data, timelines, or financial impacts.